FS Reports最新文献

{"title":"Suppression of an accessory and cavitated uterine mass with norethindrone: a case report","authors":"Hope Knochenhauer M.D. ,&nbsp;Lili Mohebbi D.O. ,&nbsp;Eric Knochenhauer M.D.","doi":"10.1016/j.xfre.2025.01.014","DOIUrl":"10.1016/j.xfre.2025.01.014","url":null,"abstract":"<div><h3>Objective</h3><div>To describe conservative management for accessory and cavitated uterine mass (ACUM) with norethindrone acetate. The patient gave signed written, informed consent authorizing publication.</div></div><div><h3>Design</h3><div>We present a case report of a patient with ACUM who desired delay in surgical management.</div></div><div><h3>Subjects</h3><div>The patient initially presented as a 16-year-old. She reported menses starting at the age of 11 years with increasing chronic pain and severe dysmenorrhea over the past 5 years. She was started on norethindrone acetate (5 mg orally once a day). Her periods were completely suppressed on this initial dose, and her pain resolved. After 4 years of conservative management, the patient requested definitive surgical management at the age of 20 years.</div></div><div><h3>Main Outcome Measures</h3><div>Abdominal surgery was performed 4 years after initial diagnosis after delay with norethindrone acetate.</div></div><div><h3>Results</h3><div>Pathology from the procedure confirmed the diagnosis of ACUM.</div></div><div><h3>Conclusion</h3><div>On the basis of this case report, for patients with severe pain and dysmenorrhea secondary to ACUM, norethindrone acetate suppression may be a viable option. Because the patient was asymptomatic with norethindrone acetate (5 mg orally once a day), there was no need to titrate the dose higher. However, if patients continue to have pain with the starting regimen, it is reasonable to titrate the dose up to the maximum dose of norethindrone acetate (15 mg orally once daily). Although the intention for this patient was to delay surgery, for patients who are poor surgical candidates or do not desire surgical management, norethindrone acetate may be a viable, long-term option.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 1","pages":"Pages 90-94"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The phenomenon of explaining the cause of poor cycle outcomes: looking under the streetlight, or the role of cognitive bias in Reproductive Endocrinology and Infertility practices. In response to: “Unexpected poor oocyte retrieval: the phenomenon of the borderline response to the Gonadotropin-Releasing Hormone (GnRH) agonist trigger”","authors":"Jennia Michaeli M.D. ,&nbsp;Heather Shapiro M.D.","doi":"10.1016/j.xfre.2025.01.018","DOIUrl":"10.1016/j.xfre.2025.01.018","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 1","pages":"Pages 97-98"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming challenges in ovarian visualization: a case report of a magnetic resonance imaging–guided oocyte retrieval resulting in live birth","authors":"Michael F. Neblett II M.D. ,&nbsp;Hakan Kula M.D. ,&nbsp;David L. Walker M.Sc. ,&nbsp;Katherine J. Nunemacher M.S. ,&nbsp;David A. Woodrum M.D., Ph.D. ,&nbsp;Samir N. Babayev M.D.","doi":"10.1016/j.xfre.2025.01.007","DOIUrl":"10.1016/j.xfre.2025.01.007","url":null,"abstract":"<div><h3>Objective</h3><div>To report a successful case of magnetic resonance imaging (MRI)–guided oocyte retrieval in a patient with challenging pelvic anatomy, extensive adhesive disease, and diminished ovarian reserve, necessitated by the inability to visualize the ovaries using transvaginal or transabdominal ultrasound.</div></div><div><h3>Design</h3><div>Case report.</div></div><div><h3>Subject</h3><div>A 33-year-old nulligravid woman with a history of ulcerative colitis, multiple pelvic and abdominal surgeries, and significant pelvic adhesive disease.</div></div><div><h3>Exposure</h3><div>Controlled ovarian stimulation was initiated using a gonadotropin-releasing hormone antagonist protocol, followed by sequential MRI and MRI-guided oocyte retrieval due to challenges in visualizing and accessing the ovaries.</div></div><div><h3>Main Outcome Measures</h3><div>Successful oocyte retrieval under MRI guidance.</div></div><div><h3>Results</h3><div>Two oocytes were retrieved from 5 aspirated follicles using MRI guidance. Both underwent intracytoplasmic sperm injection, resulting in the development of a single blastocyst, which led to a live birth via embryo transfer to a gestational carrier.</div></div><div><h3>Conclusion</h3><div>Magnetic resonance imaging–guided oocyte retrieval represents a potential technique for patients with complex pelvic anatomy or extensive adhesive disease, where traditional ultrasound-guided approaches may be inadequate. Interdisciplinary collaboration and individualized care are crucial in optimizing outcomes for patients undergoing assisted reproduction, particularly those with challenging medical histories. Further studies comparing MRI-guided and traditional ultrasound-guided oocyte retrieval in challenging cases are warranted to determine the optimal approach for these patients.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 1","pages":"Pages 39-46"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of follicle size before luteal progesterone supplementation on clinical outcomes of modified natural cycle single frozen embryo transfer","authors":"Shahryar K. Kavoussi M.D., M.P.H. ,&nbsp;Shu-Hung Chen M.S. ,&nbsp;Negar Farzaneh Ph.D. ,&nbsp;Arya Farahi Ph.D. ,&nbsp;Romtin Mehrabani-Farsi B.S. ,&nbsp;Kenneth I. Aston Ph.D. ,&nbsp;Justin Chen B.S.A. ,&nbsp;Parviz K. Kavoussi M.D.","doi":"10.1016/j.xfre.2024.12.001","DOIUrl":"10.1016/j.xfre.2024.12.001","url":null,"abstract":"<div><h3>Objective</h3><div>To determine whether follicle size at midcycle transvaginal sonography imaging before luteal progesterone supplementation predicts modified natural cycle single frozen embryo transfer (mNC-SFET) outcomes.</div></div><div><h3>Design</h3><div>Retrospective chart review.</div></div><div><h3>Subjects</h3><div>Frozen embryo transfer charts were reviewed. After inclusion and exclusion criteria were applied, data were abstracted from cases of mNC-SFET (n = 115).</div></div><div><h3>Exposure</h3><div>For group A, lead follicle measuring &lt;16 mm on day of trigger or peak +ovulation predictor kit (n = 50), and for group B, lead follicle measuring ≥16 mm on day of trigger or peak +ovulation predictor kit (n = 65).</div></div><div><h3>Main Outcome Measures</h3><div>Follicle size analyzed as possible predictor of primary outcome ongoing pregnancy rate (OPR) as well as secondary outcomes implantation rate (IR), clinical pregnancy rate (CPR), and spontaneous abortion (SAB) rate via bivariate associations and multivariate logistic regression analyses.</div></div><div><h3>Results</h3><div>Bivariate analyses showed no differences between groups in OPR (A, 48.0%, 24/50, and B, 44.6 %, 29/65), IR (A, 64.0%, 32/50, and B, 61.5%, 40/65), CPR (A, 58.0%, 29/50, and B, 52.3%, 34/65), and SAB rates (A, 25.0%, 8/32, and B, 27.5%, 11/40). Multivariate analysis to investigate potential confounding between lead follicle size and outcomes of interest showed no difference in the primary and secondary outcomes. Furthermore, multivariate analyses using lead follicle size as a continuous variable showed no difference in outcomes.</div></div><div><h3>Conclusion</h3><div>In normo-ovulatory women undergoing mNC-SFET with natural endometrial preparation with human chorionic gonadotropin trigger or luteinizing hormone surge to time frozen embryo transfer, lead follicle size before luteal phase supplementation does not impact clinical outcomes such as IR, CPR, SAB rate, or OPR.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 1","pages":"Pages 47-51"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Office of Public Affairs update: a quarterly update from the American Society for Reproductive Medicine Office of Public Affairs on key developments in reproductive health policy","authors":"Rebecca O’Connor J.D.","doi":"10.1016/j.xfre.2025.02.003","DOIUrl":"10.1016/j.xfre.2025.02.003","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 1","pages":"Page 3"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro gametogenesis in the ongoing quest to vanquish infertility: the role of epigenetics","authors":"Eli Y. Adashi M.D., M.S. ,&nbsp;Gary M. Wessel Ph.D.","doi":"10.1016/j.xfre.2024.10.001","DOIUrl":"10.1016/j.xfre.2024.10.001","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 342-343"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight-neutral approach and later sleep midpoint in adolescents with “emerging polycystic ovary syndrome phenotype” as vehicles for sustainable weight loss","authors":"Josephine Z. Kasa-Vubu M.D. ,&nbsp;Alexandra Waisanen R.D.N. ,&nbsp;Julie Sturza M.P.H. ,&nbsp;Vasantha Padmanabhan Ph.D. ,&nbsp;Louise M. O’Brien M.S., Ph.D.","doi":"10.1016/j.xfre.2024.09.001","DOIUrl":"10.1016/j.xfre.2024.09.001","url":null,"abstract":"<div><h3>Objective</h3><div>Incorporate sleep into a novel lifestyle intervention strategy in adolescents with Emerging symptoms of polycystic ovary syndrome (E-PCOS).</div></div><div><h3>Design</h3><div>A single-center cohort study.</div></div><div><h3>Setting</h3><div>University hospital-based clinic for adolescents with PCOS.</div></div><div><h3>Patients</h3><div>Forty-three girls at an age between 10 and 18 years presenting with E-PCOS between March 2015 and September 2017 with clinical signs of androgen excess and/or accelerated weight gain, acanthosis nigricans, irregular periods, or delayed menarche and followed every 6 months for a minimum of 4 visits, to October 2020.</div></div><div><h3>Interventions</h3><div>All patients received nutritional counseling, with a goal of “zero weight gain,” daily moderate physical activity goals of 45 minutes per day, and education regarding age-appropriate sleep duration. Three treatment strategies for E-PCOS symptoms were applied depending on the chief clinical complaint: anti-insulin approach with metformin; antiandrogen approach with oral contraceptive and spironolactone; and surveillance.</div></div><div><h3>Main Outcome Measures</h3><div>Body mass index (BMI) Z-score over time. Alanine Transaminase (ALT) levels as a risk factor for nonalcoholic fatty liver.</div></div><div><h3>Results</h3><div>Average number of return visits was 4 with 58% having &gt;4 return visits. Testosterone levels were correlated with ALT (<em>r</em> = 0.68). Weeknight sleep duration was less than age-appropriate recommendations for 63% of participants. Sleep midpoint correlated with ALT levels (<em>r</em> = 0.48). Despite the weight-neutral approach, regression models all demonstrated significant weight loss regardless of menarche status, metformin use, number of visits, and high vs. low ALT groups. Those with the latest sleep midpoint at baseline benefited the most, with BMI Z-score dropping significantly (interaction of time and baseline sleep midpoint from the first visit on school night).</div></div><div><h3>Conclusion</h3><div>A novel approach for adolescent girls with E-PCOS that focuses on metabolic endpoints and includes sleep duration and timing as specific targets, led to significant weight loss irrespective of treatment group.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 402-410"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No need to freeze everything: Are we striking the right balance in fertility treatments?","authors":"Lusine Aghajanova M.D., Ph.D.","doi":"10.1016/j.xfre.2024.10.003","DOIUrl":"10.1016/j.xfre.2024.10.003","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 354-355"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fresh vs. frozen: pregnancy outcomes and treatment efficacy between fresh embryo transfer vs. untested freeze-all cycles","authors":"Zoran J. Pavlovic M.D. ,&nbsp;Gabrielle E. Smotrich B.A. ,&nbsp;Erika P. New M.D. ,&nbsp;Samad Jahandideh Ph.D. ,&nbsp;Kate Devine M.D. ,&nbsp;Anthony N. Imudia M.D. ,&nbsp;Shayne Plosker M.D.","doi":"10.1016/j.xfre.2024.09.003","DOIUrl":"10.1016/j.xfre.2024.09.003","url":null,"abstract":"<div><h3>Objective</h3><div>To compare pregnancy outcomes after single blastocyst embryo transfer among patients whose first autologous embryo transfer was either a fresh embryo transfer or a frozen embryo transfer (FET) after a freeze-all, in the absence of preimplantation genetic testing for aneuploidy (PGT-A).</div></div><div><h3>Design</h3><div>A multicenter retrospective cohort analysis.</div></div><div><h3>Setting</h3><div>National multicenter fertility practice.</div></div><div><h3>Patient(s)</h3><div>A total of 8,319 autologous first blastocyst embryo transfers in the absence of PGT-A were analyzed. Of them, 6,755 transfers were fresh embryo transfer (ET) and 1,564 transfers were FET after freeze-all.</div></div><div><h3>Exposure</h3><div>Patients underwent either a fresh or a frozen initial autologous, single blastocyst transfer in the absence of PGT-A.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Primary outcome measure was live birth rate. Secondary outcome measures included positive pregnancy test, clinical pregnancy rate, and miscarriage rate.</div></div><div><h3>Result(s)</h3><div>Live birth rate was comparable between the fresh ET and FET groups in the absence of PGT-A, after performing generalized estimating equation modeling to account for age, body mass index, antral follicle count, basal follicle-stimulating hormone, progesterone on day of trigger/day of final lining check, peak estradiol during in vitro fertilization stimulation cycle, number of oocytes retrieved during ovarian stimulation cycle, and primary diagnosis. Similarly, the secondary outcome variables of positive pregnancy test, clinical pregnancy rate, and miscarriage rates were comparable between the cohorts. These findings were observed in the entire study group, within each age category of &lt;35, 35–37, 38–40, and &gt;40 and among each stratified peak estradiol group.</div></div><div><h3>Conclusion(s)</h3><div>In the absence of PGT-A, patients and fertility providers can elect to pursue either fresh ET or embryo freeze-all with subsequent FET during the first autologous in vitro fertilization cycle.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Pages 369-377"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Office of Public Affairs update: a quarterly update from the American Society for Reproductive Medicine Office of Public Affairs on key developments in reproductive health policy","authors":"Rebecca O’Connor J.D.","doi":"10.1016/j.xfre.2024.10.004","DOIUrl":"10.1016/j.xfre.2024.10.004","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 4","pages":"Page 341"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}